Atara licenses T cell therapy to Pierre Fabre for up to $640 million

As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.

Related Keywords

Germany ,United States ,Canada ,American ,Eric Ducournau ,Pierre Fabre ,Early Access Program ,Drug Administration ,Biologics License Application ,Middle East ,European Union ,Pierre Fabre Laboratories ,Cell Amp Gene Therapies ,Markets Amp Regulations ,T Cell ,Cell Therapy ,Partnership ,Stem Cell ,Iologics ,Fda ,